---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-020811"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:09:01.466499+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q2 2022 revenue up to $28.2M; net loss narrows to $0.25/share

## Summary
- Q2 net product revenue $28.2M vs $6.6M YoY; six month revenue $49.8M.
- Net loss $35.5M ($0.25/share) vs $47.0M ($0.37) in Q2 2021.
- LUPKYNIS patients on treatment ~1,274 at June 30, up 19% from Q1 2022.
- 2022 net revenue guidance reaffirmed at $115-$135M.
- Positive CHMP opinion in Europe; EC decision expected by end of Q3 2022.

## SEC filing metadata
- accession: 0001628280-22-020811
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828022020811/0001628280-22-020811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828022020811/auph-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-020811
- JSON: https://secwatch.observer/filing/0001628280-22-020811.json
- Plain text: https://secwatch.observer/filing/0001628280-22-020811.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.